Developer docs
API playgroundTry for free, no card

Search company profiles

Molecular Instruments

Full company profile

uuid00048p3

Namestring
Molecular Instruments
Legal namestring
Molecular Instruments, Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Molecular Instruments, Inc. is a privately held biotechnology company founded in 2018 and headquartered in Los Angeles, California, that commercializes Hybridization Chain Reaction (HCR) technology originally developed at the California Institute of Technology. The company's core offering is a family of reagent kits and custom probe design services for multiplex, quantitative bioimaging of RNA and protein targets in intact tissue samples. Two principal product lines — HCR Gold (enzyme-free, 1-step signal amplification supporting up to 10-plex detection) and HCR Pro (enzymatic amplification for extreme-sensitivity chromogenic or fluorescent RNA in situ hybridization) — are complemented by add-on modules for immunofluorescence, RNA flow cytometry, northern blots, single-molecule and subcellular RNA imaging, and spectral unmixing. The Infinite Catalog provides validated probe designs for any RNA target across the tree of life with no per-design fee.

The company sells through its own e-commerce storefront with quote-based pricing and 30-day payment terms, complemented by an academic discount program for universities, government labs, and non-profit research institutes. Customer segments are organized horizontally across academic research, pharmaceutical R&D, and clinical pathology/diagnostics, with secondary exposure to agricultural and veterinary applications. Distribution is increasingly augmented by channel integrations with the dominant automated staining and imaging platforms — Leica Biosystems BOND RX and BOND-III, Standard BioTools Hyperion, Biocare Medical ONCORE Pro X, and NeoPATH Pro — as well as AI-driven image analysis partners Visiopharm, Indica Labs, and Alpenglow Biosciences, and a compatibility partnership with Abcam's antibody catalog.

Revenue mechanics are tied to one-time kit and probe purchases, with custom probe design rights retained by the company for inclusion in catalog offerings. The business is founder-controlled (CEO Harry M.T. Choi and Chair Niles A. Pierce, both HCR originators from Caltech), operates with an 11–50 employee team from a single Los Angeles office, and holds an exclusive Caltech license to multiple granted HCR patents across US, EP, AU, HK, and IL jurisdictions. In November 2025 a court invalidated two competitor patents (Advanced Cell Diagnostics) and ordered £1.35M in MI's favor, materially strengthening the company's freedom to operate in RNA-ISH.

Short descriptiontext

Molecular Instruments commercializes HCR (Hybridization Chain Reaction) reagent kits and custom probe design services for multiplex quantitative RNA and protein bioimaging, serving academic, pharmaceutical, and clinical pathology customers globally via exclusive Caltech-licensed technology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multiplex bioimaging assays, in situ hybridization reagents, RNA fluorescence imaging, immunofluorescence amplification kits, spatial biology tools
Industry3 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Spatial Biology & In Situ Hybridization Reagents
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Research Kit Sales
TypeOne Time License
Description

One-time purchase of HCR reagent kits for RNA-FISH, immunofluorescence, and RNA-ISH applications. Kits include probes, amplifiers, buffers, and accessories. Individual components available for purchase separately. Prices exclude shipping, taxes, and handling.

molecularinstruments.com
2Custom Product Design Services
TypeOne Time License
Description

Custom HCR HiFi Probe design services for specific RNA targets. No design fee for standard probes; custom probe design available for specialized applications. MI retains rights to include custom products in catalog offerings.

molecularinstruments.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Pricing details2 tiers
1Standard commercial pricing for research kits
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Quote-based pricing with 30-day quote validity. Academic discount available upon registration for eligible institutions.

molecularinstruments.com
2Academic/Non-profit pricing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

University, government lab, and non-profit research institute discounts available upon account registration and verification.

molecularinstruments.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1HCR™
Description

Hybridization Chain Reaction technology platform for multiplex quantitative bioimaging

molecularinstruments.com
+6 more records
Core offering1 text field

Molecular Instruments designs, develops, and commercializes HCR (Hybridization Chain Reaction) reagent kits and custom probe design services for multiplex, quantitative, high-resolution RNA and protein bioimaging. Products span HCR Gold (enzyme-free) and HCR Pro (enzymatic) lines for RNA-FISH, immunofluorescence, combined RNA-FISH/IF, and specialized applications including flow cytometry, Northern blots, spectral imaging, and single-molecule imaging, sold to academic research labs, pharmaceutical and biotech firms, and clinical pathology customers worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Halved costs and doubled processing speed compared to existing chromogenic ISH methods
+1 more record
Product overview1 text field

Molecular Instruments offers a multi-product platform centered on HCR (Hybridization Chain Reaction) technology for multiplex quantitative bioimaging. The core platform comprises two main product lines: HCR Gold for enzyme-free signal amplification enabling 10-plex multiplex imaging across RNA-FISH, immunofluorescence (IF), and combined RNA-FISH/IF assays; and HCR Pro for enzymatic amplification providing extreme-sensitivity RNA imaging with chromogenic (RNA-CISH) or fluorescent staining options. Supporting add-on modules include HCR Gold 2°IF for different-species protein multiplexing, RNA Flow Cytometry, Northern Blots, and specialized spectral imaging and subcellular/single-molecule quantitative imaging capabilities. The platform is complemented by an Infinite Catalog service for custom probe design and integrates with automated staining instruments from Leica Biosystems (BOND RX/III) and NeoPATH Pro, as well as Standard BioTools imaging systems.

Product and service5 records
1HCR Gold RNA-FISH
CategoryHCR Gold reagent kit (RNA-FISH)
Description

10-plex, quantitative, high-resolution, enzyme-free RNA fluorescence in situ hybridization kit with automatic background suppression for multiplex bioimaging across diverse sample types, for academic, pharmaceutical, and clinical pathology researchers.

2HCR Gold IF
CategoryHCR Gold reagent kit (immunofluorescence)
Description

Multiplex immunofluorescence kit using the HCR HiFi Encoder to encode quantitative 1-step signal amplification onto the user's own primary antibodies, enabling same-species/isotype multiplexing without cross-reactivity, for researchers needing flexible multiplex protein detection.

3HCR Gold RNA-FISH/IF
CategoryHCR Gold reagent kit (combined RNA-FISH/IF)
Description

Unified multiplex quantitative high-resolution combined RNA-FISH and immunofluorescence kit using 1-step HCR Gold signal amplification for simultaneous detection of up to 10 RNA and/or protein targets, for translational research and biomarker discovery.

4HCR Pro RNA-ISH
CategoryHCR Pro reagent kit (RNA-ISH)
Description

Enzymatic-amplification RNA imaging kit with chromogenic (RNA-CISH) or fluorescent (RNA-FISH) staining and a protease-free workflow for extreme-sensitivity RNA in situ hybridization when signal-to-background is critical, for clinical pathology and demanding research applications.

5Infinite Catalog (Custom HCR HiFi Probe Design Service)
CategoryCustom probe design service
Description

Custom HCR HiFi Probe design service covering any target RNA in any organism across the tree of life with no design fee, backed by the HCR HiFi Probe Promise, for researchers needing validated probes for non-standard or novel RNA targets.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-05
Description

Launch of NISH (largest ready-to-use, fully automated ISH library) powered by HCR Pro, exclusively available worldwide on NeoPATH Pro automated staining platform. Features over 17 ready-to-use ISH probes with run times as little as 5.5 hours, powered by protease-free HCR Pro RNA-ISH technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Launch of fully ambient-temperature HCR Pro RNA-ISH on the BOND-III autostaining platform for clinical-grade RNA in situ hybridization. The technology eliminates heat- and enzyme-driven variability to preserve tissue morphology and deliver consistent high signal-to-background performance.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

Strategic collaboration to develop amplified multi-omic readouts for imaging mass cytometry. Integration aims to improve sensitivity and flexibility by enabling amplified detection of RNA and protein markers for multi-omic analysis within a single workflow using the Hyperion Imaging System.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-21
Description

Broad compatibility announced between MI's HCR HiFi Encoder and Abcam's RabMAb and mouse antibody portfolio. Collaboration enables detection of up to 10 targets simultaneously in a single sample, enhancing multiplex immunofluorescence and RNA imaging workflows.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-06-03
Description

Partnership to advance 3D RNA imaging in intact biological samples. Collaboration enables deeper tissue penetration and 3D reconstruction capabilities using MI's HCR technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-22
Description

Leica Biosystems partnership enables HCR Pro RNA-ISH technology integration with BOND RX and BOND RXm research staining instruments for automated multiplex immunofluorescence workflows. MI announced release of HCR Gold IF on the BOND RX in June 2026, enabling flexible multiplex protein detection using off-the-shelf primary antibodies on an established automation platform.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-11-06
Description

Strategic partnership to combine AI-driven precision pathology with HCR Pro assays to advance clinical-grade RNA-ISH. Integration of AI image analysis with MI's clinical-grade RNA detection technology.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2024-04-05
Description

Partnership to advance AI-powered quantitative image analysis with HCR RNA-ISH technology. Integration enables automated quantification of MI's multiplex imaging data.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-04
Description

Collaboration to advance ISH services powered by HCR RNA-ISH technology. HistoWiz provides pathology services using MI's RNA-ISH products.

Strategic tierStrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-05
Description

Partnership to revolutionize automated bioimaging through ONCORE Pro X and HCR RNA-ISH assays. Integration of MI's RNA detection technology with Biocare's automated staining platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of the Hyperion Imaging System for imaging mass cytometry; MI is a strategic partner integrating HCR amplification into Hyperion workflows. Overlaps with MI in highly multiplexed tissue imaging for translational research.

TypeEmerging player
Description

Major antibody supplier whose RabMAb and mouse antibody portfolio is now broadly compatible with MI's HCR HiFi Encoder. Adjacent/ecosystem competitor in multiplex immunofluorescence via its own antibody-pairing kits, and a distribution amplifier for MI.

TypeDirect peer
Description

Developer of the RNAscope in situ hybridization platform — the dominant commercial ISH technology and MI's primary direct competitor. Recently involved in IP litigation with MI that MI won, underscoring their direct competitive overlap in RNA-ISH for research and clinical pathology.

TypeBroad incumbent
Description

Owner of the BOND family of clinical autostainers on which MI's HCR Gold and HCR Pro chemistries are integrated; also markets BOND-MAX and ancillary IHC/ISH reagents. Both partner and broad competitor in clinical pathology workflows.

TypeDirect peer
Description

Channel partner integrating MI's HCR RNA-ISH chemistry onto ONCORE Pro X and NeoPATH Pro automated staining platforms, and via Empire Genomics distributing the NISH ready-to-use probe library. Direct overlap in automated clinical ISH workflows.

TypeDirect peer
Description

Spatial biology competitor with CosMx SMI single-molecule imaging and GeoMx digital spatial profiling platforms. Directly competes with MI's HCR-based multiplex RNA imaging for spatial transcriptomics and biomarker discovery.

TypeOthers
Description

AI-powered quantitative pathology image analysis provider integrated with MI's HCR RNA-ISH workflows. Adjacent ecosystem participant — neither competes with nor manufactures reagents, but enables quantitative read-out of MI's multiplex images.

TypeDirect peer
Description

Multiplex immunofluorescence and spatial phenotyping company with PhenoCycler-Fusion and OPAL chemistry. Competes with MI's HCR Gold IF / HiFi Encoder in multiplex protein imaging, particularly in immuno-oncology and translational research.

TypeOthers
Description

AI-driven precision pathology platform partnered with MI for clinical-grade RNA-ISH image analysis. Ecosystem enabler for MI's translational and clinical diagnostic positioning; does not directly compete in reagent chemistry.

TypeDirect peer
Description

Spatial biology leader with Xenium (in situ imaging) and Visium (spatial transcriptomics) platforms that compete with MI in multiplex RNA imaging, particularly for translational and pharma biomarker applications. Targets overlapping academic and pharma customer segments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molecular Instruments

Spatial Biology & In Situ Hybridization Reagentsmolecularinstruments.com

Molecular Instruments commercializes HCR (Hybridization Chain Reaction) reagent kits and custom probe design services for multiplex quantitative RNA and protein bioimaging, serving academic, pharmaceutical, and clinical pathology customers globally via exclusive Caltech-licensed technology.

What Molecular Instruments does

Molecular Instruments, Inc. is a privately held biotechnology company founded in 2018 and headquartered in Los Angeles, California, that commercializes Hybridization Chain Reaction (HCR) technology originally developed at the California Institute of Technology. The company's core offering is a family of reagent kits and custom probe design services for multiplex, quantitative bioimaging of RNA and protein targets in intact tissue samples. Two principal product lines — HCR Gold (enzyme-free, 1-step signal amplification supporting up to 10-plex detection) and HCR Pro (enzymatic amplification for extreme-sensitivity chromogenic or fluorescent RNA in situ hybridization) — are complemented by add-on modules for immunofluorescence, RNA flow cytometry, northern blots, single-molecule and subcellular RNA imaging, and spectral unmixing. The Infinite Catalog provides validated probe designs for any RNA target across the tree of life with no per-design fee.

The company sells through its own e-commerce storefront with quote-based pricing and 30-day payment terms, complemented by an academic discount program for universities, government labs, and non-profit research institutes. Customer segments are organized horizontally across academic research, pharmaceutical R&D, and clinical pathology/diagnostics, with secondary exposure to agricultural and veterinary applications. Distribution is increasingly augmented by channel integrations with the dominant automated staining and imaging platforms — Leica Biosystems BOND RX and BOND-III, Standard BioTools Hyperion, Biocare Medical ONCORE Pro X, and NeoPATH Pro — as well as AI-driven image analysis partners Visiopharm, Indica Labs, and Alpenglow Biosciences, and a compatibility partnership with Abcam's antibody catalog.

Revenue mechanics are tied to one-time kit and probe purchases, with custom probe design rights retained by the company for inclusion in catalog offerings. The business is founder-controlled (CEO Harry M.T. Choi and Chair Niles A. Pierce, both HCR originators from Caltech), operates with an 11–50 employee team from a single Los Angeles office, and holds an exclusive Caltech license to multiple granted HCR patents across US, EP, AU, HK, and IL jurisdictions. In November 2025 a court invalidated two competitor patents (Advanced Cell Diagnostics) and ordered £1.35M in MI's favor, materially strengthening the company's freedom to operate in RNA-ISH.

Molecular Instruments firmographics

Firmographics
Name
Molecular Instruments
Legal name
Molecular Instruments, Inc.
Website
https://molecularinstruments.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Molecular Instruments commercializes HCR (Hybridization Chain Reaction) reagent kits and custom probe design services for multiplex quantitative RNA and protein bioimaging, serving academic, pharmaceutical, and clinical pathology customers globally via exclusive Caltech-licensed technology.
Ownership category
akta.pro rank

Molecular Instruments industry classification

Industry
Product category
Spatial Biology & In Situ Hybridization Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Multiplex bioimaging assays
  • In situ hybridization reagents
  • RNA fluorescence imaging
  • Immunofluorescence amplification kits
  • Spatial biology tools

Where Molecular Instruments is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Molecular Instruments business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Research Kit Sales: One-time purchase of HCR reagent kits for RNA-FISH, immunofluorescence, and RNA-ISH applications. Kits include probes, amplifiers, buffers, and accessories. Individual components available for purchase separately. Prices exclude shipping, taxes, and handling.
  2. Custom Product Design Services: Custom HCR HiFi Probe design services for specific RNA targets. No design fee for standard probes; custom probe design available for specialized applications. MI retains rights to include custom products in catalog offerings.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goStandard commercial pricing for research kits
One time/ perpetual licensePay-as-you-goAcademic/Non-profit pricing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Molecular Instruments product offering

Product offering

Core offering

Molecular Instruments designs, develops, and commercializes HCR (Hybridization Chain Reaction) reagent kits and custom probe design services for multiplex, quantitative, high-resolution RNA and protein bioimaging. Products span HCR Gold (enzyme-free) and HCR Pro (enzymatic) lines for RNA-FISH, immunofluorescence, combined RNA-FISH/IF, and specialized applications including flow cytometry, Northern blots, spectral imaging, and single-molecule imaging, sold to academic research labs, pharmaceutical and biotech firms, and clinical pathology customers worldwide.

Product overview

Molecular Instruments offers a multi-product platform centered on HCR (Hybridization Chain Reaction) technology for multiplex quantitative bioimaging. The core platform comprises two main product lines: HCR Gold for enzyme-free signal amplification enabling 10-plex multiplex imaging across RNA-FISH, immunofluorescence (IF), and combined RNA-FISH/IF assays; and HCR Pro for enzymatic amplification providing extreme-sensitivity RNA imaging with chromogenic (RNA-CISH) or fluorescent staining options. Supporting add-on modules include HCR Gold 2°IF for different-species protein multiplexing, RNA Flow Cytometry, Northern Blots, and specialized spectral imaging and subcellular/single-molecule quantitative imaging capabilities. The platform is complemented by an Infinite Catalog service for custom probe design and integrates with automated staining instruments from Leica Biosystems (BOND RX/III) and NeoPATH Pro, as well as Standard BioTools imaging systems.

Differentiator

Problem solved

Functional benefit

Brands

  • HCR™: Hybridization Chain Reaction technology platform for multiplex quantitative bioimaging
  • HCR™ Gold
  • HCR™ Pro
  • HCR™ HiFi Encoder
  • Infinite Catalog
  • Imaging the Molecules of Life®
  • By Scientists For Scientists®

Products and services

  • HCR Gold RNA-FISH 10-plex, quantitative, high-resolution, enzyme-free RNA fluorescence in situ hybridization kit with automatic background suppression for multiplex bioimaging across diverse sample types, for academic, pharmaceutical, and clinical pathology researchers.
  • HCR Gold IF Multiplex immunofluorescence kit using the HCR HiFi Encoder to encode quantitative 1-step signal amplification onto the user's own primary antibodies, enabling same-species/isotype multiplexing without cross-reactivity, for researchers needing flexible multiplex protein detection.
  • HCR Gold RNA-FISH/IF Unified multiplex quantitative high-resolution combined RNA-FISH and immunofluorescence kit using 1-step HCR Gold signal amplification for simultaneous detection of up to 10 RNA and/or protein targets, for translational research and biomarker discovery.
  • HCR Pro RNA-ISH Enzymatic-amplification RNA imaging kit with chromogenic (RNA-CISH) or fluorescent (RNA-FISH) staining and a protease-free workflow for extreme-sensitivity RNA in situ hybridization when signal-to-background is critical, for clinical pathology and demanding research applications.
  • Infinite Catalog (Custom HCR HiFi Probe Design Service) Custom HCR HiFi Probe design service covering any target RNA in any organism across the tree of life with no design fee, backed by the HCR HiFi Probe Promise, for researchers needing validated probes for non-standard or novel RNA targets.

Quantifiable outcome

  • Halved costs and doubled processing speed compared to existing chromogenic ISH methods
  • +1 more outcomes

Companies that use Molecular Instruments

Customer profile

Segments4 records

Ideal customer profiles3 records

Molecular Instruments technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

Feature5 records

Molecular Instruments partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, strategic and minor.

  • Empire Genomics (Biocare Medical)coreChannel Partner/ Reseller/ Distributor · 5 May 2026Launch of NISH (largest ready-to-use, fully automated ISH library) powered by HCR Pro, exclusively available worldwide on NeoPATH Pro automated staining platform. Features over 17 ready-to-use ISH probes with run times as little as 5.5 hours, powered by protease-free HCR Pro RNA-ISH technology.
  • Leica Biosystems (BOND-III)coreStrategic or Co-development Partner · 17 February 2026Launch of fully ambient-temperature HCR Pro RNA-ISH on the BOND-III autostaining platform for clinical-grade RNA in situ hybridization. The technology eliminates heat- and enzyme-driven variability to preserve tissue morphology and deliver consistent high signal-to-background performance.
  • Standard BioToolscoreStrategic or Co-development Partner · 19 November 2025Strategic collaboration to develop amplified multi-omic readouts for imaging mass cytometry. Integration aims to improve sensitivity and flexibility by enabling amplified detection of RNA and protein markers for multi-omic analysis within a single workflow using the Hyperion Imaging System.
  • AbcamcoreTechnology or Integration · 21 October 2025Broad compatibility announced between MI's HCR HiFi Encoder and Abcam's RabMAb and mouse antibody portfolio. Collaboration enables detection of up to 10 targets simultaneously in a single sample, enhancing multiplex immunofluorescence and RNA imaging workflows.
  • Alpenglow BiosciencesstrategicStrategic or Co-development Partner · 3 June 2025Partnership to advance 3D RNA imaging in intact biological samples. Collaboration enables deeper tissue penetration and 3D reconstruction capabilities using MI's HCR technology.
  • Leica BiosystemscoreStrategic or Co-development Partner · 22 January 2025Leica Biosystems partnership enables HCR Pro RNA-ISH technology integration with BOND RX and BOND RXm research staining instruments for automated multiplex immunofluorescence workflows. MI announced release of HCR Gold IF on the BOND RX in June 2026, enabling flexible multiplex protein detection using off-the-shelf primary antibodies on an established automation platform.
  • VisiopharmstrategicStrategic or Co-development Partner · 6 November 2024Strategic partnership to combine AI-driven precision pathology with HCR Pro assays to advance clinical-grade RNA-ISH. Integration of AI image analysis with MI's clinical-grade RNA detection technology.
  • Indica LabsstrategicTechnology or Integration · 5 April 2024Partnership to advance AI-powered quantitative image analysis with HCR RNA-ISH technology. Integration enables automated quantification of MI's multiplex imaging data.
  • HistoWizminorChannel Partner/ Reseller/ Distributor · 4 April 2024Collaboration to advance ISH services powered by HCR RNA-ISH technology. HistoWiz provides pathology services using MI's RNA-ISH products.
  • Biocare MedicalstrategicChannel Partner/ Reseller/ Distributor · 5 January 2024Partnership to revolutionize automated bioimaging through ONCORE Pro X and HCR RNA-ISH assays. Integration of MI's RNA detection technology with Biocare's automated staining platform.

Scale indicators2 records

Recent moves6 records

Expansion highlights7 records

Molecular Instruments competitors and assessment

Company assessment

Direct peers

  • Standard BioTools (formerly Fluidigm): Developer of the Hyperion Imaging System for imaging mass cytometry; MI is a strategic partner integrating HCR amplification into Hyperion workflows. Overlaps with MI in highly multiplexed tissue imaging for translational research.
  • Advanced Cell Diagnostics (Bio-Techne): Developer of the RNAscope in situ hybridization platform — the dominant commercial ISH technology and MI's primary direct competitor. Recently involved in IP litigation with MI that MI won, underscoring their direct competitive overlap in RNA-ISH for research and clinical pathology.
  • Biocare Medical: Channel partner integrating MI's HCR RNA-ISH chemistry onto ONCORE Pro X and NeoPATH Pro automated staining platforms, and via Empire Genomics distributing the NISH ready-to-use probe library. Direct overlap in automated clinical ISH workflows.
  • NanoString Technologies: Spatial biology competitor with CosMx SMI single-molecule imaging and GeoMx digital spatial profiling platforms. Directly competes with MI's HCR-based multiplex RNA imaging for spatial transcriptomics and biomarker discovery.
  • Akoya Biosciences: Multiplex immunofluorescence and spatial phenotyping company with PhenoCycler-Fusion and OPAL chemistry. Competes with MI's HCR Gold IF / HiFi Encoder in multiplex protein imaging, particularly in immuno-oncology and translational research.
  • 10x Genomics: Spatial biology leader with Xenium (in situ imaging) and Visium (spatial transcriptomics) platforms that compete with MI in multiplex RNA imaging, particularly for translational and pharma biomarker applications. Targets overlapping academic and pharma customer segments.

Emerging players

  • Abcam: Major antibody supplier whose RabMAb and mouse antibody portfolio is now broadly compatible with MI's HCR HiFi Encoder. Adjacent/ecosystem competitor in multiplex immunofluorescence via its own antibody-pairing kits, and a distribution amplifier for MI.

Broad incumbents

  • Leica Biosystems (Danaher): Owner of the BOND family of clinical autostainers on which MI's HCR Gold and HCR Pro chemistries are integrated; also markets BOND-MAX and ancillary IHC/ISH reagents. Both partner and broad competitor in clinical pathology workflows.

Others

  • Indica Labs: AI-powered quantitative pathology image analysis provider integrated with MI's HCR RNA-ISH workflows. Adjacent ecosystem participant — neither competes with nor manufactures reagents, but enables quantitative read-out of MI's multiplex images.
  • Visiopharm: AI-driven precision pathology platform partnered with MI for clinical-grade RNA-ISH image analysis. Ecosystem enabler for MI's translational and clinical diagnostic positioning; does not directly compete in reagent chemistry.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Molecular Instruments social profiles

Digital presence

Molecular Instruments financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molecular Instruments leadership team

Management profile

Number of profiles

Profiles3 records

Molecular Instruments funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molecular Instruments M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecular Instruments

What does Molecular Instruments do?

Molecular Instruments designs, develops, and commercializes HCR (Hybridization Chain Reaction) reagent kits and custom probe design services for multiplex, quantitative, high-resolution RNA and protein bioimaging. Products span HCR Gold (enzyme-free) and HCR Pro (enzymatic) lines for RNA-FISH, immunofluorescence, combined RNA-FISH/IF, and specialized applications including flow cytometry, Northern blots, spectral imaging, and single-molecule imaging, sold to academic research labs, pharmaceutical and biotech firms, and clinical pathology customers worldwide.

Is Molecular Instruments a public or private company?

Molecular Instruments is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Molecular Instruments founded?

Molecular Instruments was founded in 2018. It employs 11 to 50 people.

Where is Molecular Instruments based?

Molecular Instruments is headquartered in Los Angeles, United States, in the North America region.

How does Molecular Instruments make money?

Two revenue lines are on record. Research Kit Sales are the primary driver. The others are custom Product Design Services.

Who are Molecular Instruments's main competitors?

Direct peers on record are Standard BioTools (formerly Fluidigm), Advanced Cell Diagnostics (Bio-Techne), Biocare Medical, NanoString Technologies, Akoya Biosciences and 10x Genomics. Abcam is listed as an emerging player. Leica Biosystems (Danaher) is listed as a broad incumbent. Others are Indica Labs and Visiopharm.

Does Molecular Instruments have an API?

No public API is recorded for Molecular Instruments.

What industry is Molecular Instruments in?

Molecular Instruments's product category is Spatial Biology & In Situ Hybridization Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageMolecular Instruments Announces HCR™ Gold IF for Multiplex Protein Imaging on Biocare Medical’s ONCORE Pro XMolecular Instruments announced HCR Gold IF for multiplex protein imaging on Biocare Medical's ONCORE Pro X automated slide staining system. The assay uses off-the-shelf primary antibodies, avoiding stripping and custom conjugation, and is available to order today.FinancialContent Business PageMolecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining InstrumentMolecular Instruments announced the release of HCR™ Gold IF on the BOND RX research staining instrument from Leica Biosystems, enabling automated multiplex immunofluorescence workflows for tissue analysis. The offering allows researchers to perform flexible multiplex protein detection using off-the-shelf primary antibodies on an established automation platform, without requiring stripping workflows or custom antibody conjugations. This release supports research teams in spatial biology and translational research seeking higher throughput, reproducibility, and walkaway convenience in multiplex protein detection.LeicabiosystemsHCR Gold IF Released On The BOND RXMolecular Instruments released HCR Gold IF on Leica Biosystems' BOND RX stainer, enabling flexible multiplex immunofluorescence with off-the-shelf primary antibodies. The assay supports multiple antibodies from the same host species without stripping workflows, and encoding completes in minutes at room temperature. The release aims to make higher-plex IF more practical and reproducible for research teams.GlobeNewswireLaboratory Developed Tests Market Size to Reach USD 28.31 Billion by 2035 | SNS InsiderThe laboratory developed tests market was valued at USD 14.27 billion in 2025 and is projected to reach USD 28.31 billion by 2035, a CAGR of 7.11%. Growth is driven by precision oncology, molecular diagnostics, and next-generation sequencing, with North America leading at 36.4% share.PR NewswireMolecular Instruments & Empire Genomics Launch NISH Powered by HCR™ Pro: The Largest Ready-to-Use, Fully Automated ISH Library, Exclusively Available Worldwide on NeoPATH ProEmpire Genomics (a Biocare Medical company) and Molecular Instruments have launched NISH, described as the largest ready-to-use, fully automated in situ hybridization (ISH) library for research, exclusively available on the NeoPATH Pro automated staining platform. The product features over 17 ready-to-use ISH probes with run times as little as 5.5 hours, powered by HCR™ Pro RNA-ISH technology that uses a protease-free approach to preserve tissue morphology and protein target integrity. The collaboration aims to address barriers to RNA-ISH adoption, including workflow complexity, limited automation, and probe access for research laboratories conducting biomarker and translational research.openPR.comTop Players and Market Competition in the In Situ Hybridization IndustryThe in situ hybridization market is projected to reach $3.08 billion by 2030 with an 11.3% compound annual growth rate, driven by rising demand for personalized medicine diagnostics, AI-driven image analysis, and genomic research investments. Danaher Corporation acquired Abcam plc for $5.7 billion in December 2023 to broaden its diagnostics and reagent portfolio and enhance molecular assay development capabilities. Molecular Instruments launched HCR RNA-CISH kits in February 2023 that deliver superior performance by halving costs and doubling processing speed compared to existing chromogenic ISH methods.MorningstarMolecular Instruments Announces Fully Ambient-Temperature HCR™ Pro RNA-ISH on the BOND-III, Setting a New Standard for Clinical AutomationMolecular Instruments announced the launch of fully ambient-temperature HCR™ Pro RNA-ISH on the BOND-III autostaining platform, a clinical-grade RNA in situ hybridization product engineered for consistency, tissue preservation, and scalable automation in pathology workflows. Unlike conventional RNA-ISH workflows that depend on enzymatic digestion and elevated temperatures, HCR™ Pro operates entirely at ambient temperature to minimize heat-driven variability and preserve fragile patient samples. The product is now available for order through MI's webstore and integrates into existing BOND-III workflows without requiring software updates.Business Wire BlogMolecular Instruments Announces Fully Ambient-Temperature HCR™ Pro RNA-ISH on the BOND-III, Setting a New Standard for Clinical AutomationMolecular Instruments announced the availability of its HCR Pro RNA-ISH assay on the BOND-III autostaining platform, introducing a fully ambient-temperature, protease-free workflow for clinical-grade RNA in situ hybridization. The technology eliminates heat- and enzyme-driven variability to preserve tissue morphology and deliver consistent high signal-to-background performance across patient specimens. This launch expands clinical access to high-performance RNA-ISH on one of the most widely adopted autostaining platforms in pathology.BioSpaceMolecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass CytometryMolecular Instruments and Standard BioTools announced a strategic collaboration to integrate HCR imaging technologies into Standard BioTools' Hyperion Imaging System for next-generation Imaging Mass Cytometry workflows. This partnership enables amplified detection of both RNA and protein using any primary antibody, aiming to enhance the sensitivity and flexibility of spatial biology research. Joint development activities are currently underway with early-access opportunities available for collaborators.GenomeWebEU Patent Court Rejects Bio-Techne Infringement Allegations Against Molecular InstrumentsA European Union court rejected patent infringement allegations by Bio-Techne against Molecular Instruments, finding that Molecular Instruments' HCR 3.0 technology did not infringe Bio-Techne's European patents covering RNAscope in situ hybridization technology. Bio-Techne had sought damages and an injunction to stop alleged infringement of patents No. 1,910,572 and No. 2,500,439 in certain European markets, with the patents set to expire in June 2026. The ruling follows a 2024 decision by the UK Patents Court, which had found the same two patents invalid on separate grounds.